Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report)'s stock price fell 8.3% during trading on Wednesday . The stock traded as low as $4.84 and last traded at $4.92. 2,788,046 shares changed hands during trading, an increase of 84% from the average session volume of 1,518,937 shares. The stock had previously closed at $5.36.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $12.20.
Read Our Latest Analysis on TNGX
Tango Therapeutics Stock Performance
The stock has a market cap of $543.03 million, a P/E ratio of -4.11 and a beta of 1.24. The stock has a 50-day moving average price of $2.75 and a 200-day moving average price of $2.50.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $6.73 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. Sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tango Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of TNGX. Los Angeles Capital Management LLC bought a new stake in Tango Therapeutics in the 4th quarter worth approximately $218,000. Charles Schwab Investment Management Inc. raised its stake in shares of Tango Therapeutics by 5.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company's stock worth $1,586,000 after acquiring an additional 26,192 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $45,000. Swiss National Bank lifted its holdings in shares of Tango Therapeutics by 13.1% in the 4th quarter. Swiss National Bank now owns 94,900 shares of the company's stock worth $293,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Tango Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after purchasing an additional 3,831 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.